Kiniksa Pharmaceuticals International, plc KNSA Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported contract liabilities, non-current of $31.81M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current decreased by 0.0% year-over-year, from $31.81M to $31.81M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current?
- Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's contract liabilities, non-current has grown at a 38.4% compound annual growth rate (CAGR), from $12M to $31.81M.